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Background:  Type 2 diabetes mellitus, as a noncommunicable disease, is the 
main public health challenge in the 21st century. The prevalence of diabetes 
mellitus adjusted for the world population in Iran was 8% until the year 2010. 
Lipid levels are considered as important parameters to be evaluated, as high serum 
lipid levels are often reported as a complication in patients with diabetes mellitus. 
It is claimed that functional foods may improve complications of diabetes 
mellitus, so this study was designed to evaluate the effects of high performance 
inulin on glycemic status and lipid profile of women with type 2 diabetes. 
Methods: The study was a randomized controlled clinical trial. Forty-nine type 2 
diabetic females (fiber intake <30g/d, 25<BMI<35 kg/m2) were divided into two 
groups. Patients in the intervention group (n=24) received 10g/d inulin and 
patients in the control group (n=25) received 10g/d maltodextrin for 8 weeks. 
Glycemic status and lipid profile indices were measured pre and post intervention. 
Data were analyzed using SPSS software (verision11.5). Paired, unpaired t-test and 
ANCOVA were used to compare quantitative variables. 
Results:  Supplementation with inulin caused a significant reduction in FBS 
(8.50%), HbA1c (10.40%), total cholesterol (12.90%), triglyceride (23.60 %), LDL-
c (35.30 %), LDL-c/HDL-c ratio (16.25%) and TC/HDL-c ratio (25.20%) and 
increased HDL-c (19.90%). The changes for the control group parameters were 
not significant at the end of study.  
Conclusion: Inulin may help to control diabetes and its complications via 
improving glycemic and lipid parameters.  
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Introduction 
 
Diabetes mellitus (DM) is considered as 
a non-communicable disease and main public 
health challenge in developing and developed 
countries
1. The prevalence of diabetes was 171 
million in the year 2000. The total number of 
diabetic patients will be 366 million by the 
year 2030
2. The prevalence of DM adjusted 
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for the world population in Iran was 8%, and 
its health expenses was approximately 600 
million US dollars in the year 2010
3. Diabetes 
mellitus is associated with insulin resistance, 
hyperinsulinemia, hyperglycemia and bio-
chemical alterations in lipid metabolism
4. 
Cardiovascular disease (CVD) is the primary 
cause of death in type 2 diabetes
5. The relative 
risk for CVD is 2 to 4 fold higher in DM than 
in nondiabetic patients
6. Dyslipidemia has 
been known as a risk factor for cardiovascular 
complications in type 2 DM. The typical lipid 
abnormalities in type 2 diabetic adults 
comprise low levels of HDL cholesterol, high 
levels of triglycerides and a dominance of 
small, dense LDL particles
7.  
Recently, functional foods are consi-
dered in the management of type 2 diabetes 
and its complications
8. Inulin-type fructans are 
a group of functional foods, which naturally 
found in leek, wheat, onion, chicory root 
garlic, and banana. Inulin-type fructans are 
group of carbohydrate, which is classified as 
nonviscous, soluble and fermentable fibers. 
High performance inulin (HP Inulin) is a pre-
biotic with long-chain; high-molecular weight 
mixes of inulin-type fructans. This type of in-
ulin is incorporated as sugar and /or fat subs-
titute into drinks and desserts, baked goods, 
and milk products. Intake of 5-8 g/d inulin 
should be sufficient to make a positive effect 
on the gut microflora. Possible side effect of 
inulin-type fructans intake is gut discomfort 
due to gas production, reported at doses 
>20g/d
9. 
In animal studies, inulin-type fructans 
can reduce blood glucose and lipid profile, 
especially triglycerides
10,11. According to our 
knowledge, all human studies have evaluated 
the effects of fructooligosaccharides on di-
abetic patients and there is no study to eva-
luate the impact of inulin HP in these 
patients
12-14. The results obtained from several 
studies on the effects of 
fructooligosaccharides in diabetic patients are 
different. One study showed positive effects 
of oligofructose on blood glucose and lipid 
profile in diabetic patients
12. In contrast, some 
other studies reported no effects for inulin-
type fructans supplementation in diabetic 
patients
13,14. It has been suggested to design 
further randomized controlled trials (RCT) in 
order to determine the effects of inulin-type 
fructans, inulin, and oligofructose on blood 
glucose
15 and lipid profile
16 in humans.  
The present trial was conducted to as-
sess the effects of HP inulin on serum glucose 
indices and lipid profile in women with type 2 
diabetes.  
 
Materials and Methods 
 
Subjects 
In this trial, sixty- five DM females aged 
between 20-65 yr were voluntarily recruited 
from Iran Diabetes Society and Endocrinol-
ogy as well as Metabolism clinics of Tabriz 
University of Medical Sciences. Inclusion 
criteria were: having DM > 6 months, using 
anti-diabetic drugs, normal diet and Body 
Mass Index (BMI) >25 kg/m
2 during and in 
the last 3 months. Diabetes  mellitus was 
defined as a fasting glucose ≥126 mg/dl
17. 
Patients were excluded if they had  history of 
gastrointestinal, cardiovascular, renal, thyroid, 
liver, pancreatic diseases, being pregnant or 
lactating, consuming pre or probioticsُ  
products during and 2 weeks prior to the 
intervention, antibiotics, antacids, alcohol, 
anti-diarrheal, anti-inflammatory, lipid-
lowering, laxatives drugs and individual with a 
typical fiber intake >30g. At the beginning of 
trial, demographic data including age, drugs, 
diabetes duration (years) were collected using 
a questionnaire. The Ethics Committee of the 
Tabriz University of Medical Sciences 
provided ethical approval for the trial, and 
written informed consent was obtained from 
each patient. The approval of trial was 
registered on the Iranian Registry of Clinical 
Trials website (www.irct.ir/, 
IRCT201110293253N4). 
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Experimental design 
Participants were randomly divided into 
2 groups using a block randomization proce-
dure based on BMI and age. Intervention 
group received 10 g/d inulin HP supplement 
(Sensus, Borchwef 3, 4704 RG Roosendaal the 
Netherlands) and control group received sim-
ilar amounts of maltodextrin as placebo (Ji-
ujiang Hurirong Trade CO., LTD, China 
(mainland)) for 8 weeks. Both maltodextrin 
and inulin have similar taste and appearance
18, 
which were provided to subjects in similar 
opaque packages. Patients received half of 
packages at the beginning and the remaining at 
4
th week of the study. In order to minimize 
withdrawal and ensure to consumption of sup-
plements, the patients received a phone call 
every week. Throughout the trial, subjects were 
asked to have usual physical activity and diet.  
 
Anthropometric and dietary intake as-
sessment 
Anthropometric indices including body 
weight and height were measured at baseline 
and at the end of the trial. Dietary intakes 
were evaluated using a 3-day food dairy (two 
usual days and one weekend day) at baseline 
and at the end of the trial. Before the inter-
vention, all patients were provided instruc-
tions how to use food scale and record their 
food intake. After recording day, each patient 
received a phone call for renewed recording 
food intake by trained person. Dietary intakes 
were analyzed using the nutritionist 4 software 
(First Databank Inc., Hearst Corp., San 
Bruno, CA) containing the database from 
tables of content and nutritional value of Ira-
nian food products.  
 
Biochemical indices 
At baseline and at the end of trial, after 
an overnight fasting 10 ml venous blood sam-
ples were collected and transferred into two 
vacutainer tube, one containing EDTA for 
measurement of blood HbA1c and the other 
containing sodium fluoride for glucose and li-
pid profile. Serum samples were separated 
from whole blood by centrifugation at 2500 
rpm for 10 min (Beckman Avanti J-25; Beck-
man Coulter, Brea, CA) at room temperature. 
All parameters were analyzed on the day of 
sampling. FBS concentration was measured by 
the enzymatic methods using an Abbot Model 
Aclyon 300, USA auto analyzer with kits from 
Pars-Azmone (Tehran, Iran). Glycosylated he-
moglobin (HbA1c) was determined in whole 
blood using an automated high performance 
liquid chromatography analyzer with comm.-
ercially Bio-Rad D-10 Laboratories, Schilti-
gheim, France kit. 
The levels of serum total cholesterol 
(TC), high-density lipoprotein (HDL-c)  and  
triglyceride (TG) were measured by enzymatic 
colorimetric methods with commercial kits 
(Cholesterol CHOD-PAP and Triglycerides 
GPO-PAP; Pars-Azmone, IRI) on an auto-
matic analyzer (Abbott, model Alcyon 300-
USA)
19. Serum Low-density lipoprotein (LDL-c) 
was calculated according to the Friedewald 
equation
20. Since the TC/HDL-C and LDL-
C/HDL-C ratios determine the relative risk of 
coronary artery disease, they were also calcu-
lated in this trail
21. 
 
Statistical Analyses 
Data were analyzed using SPSS software 
(version 11.5; SPSS Inc., Chicago, IL). The 
results were expressed as mean ± standard 
deviation. The normality of the distribution of 
data was evaluated by the one-sample Kolmo-
gorov-Smirnov test. Paired, independent t test 
and ANCOVA were used to compare numeri-
cal data. Drugs used in two groups were com-
pared using the Mann-Whitney U test. Analysis 
of covariance was used to identify any dif-
ferences between the two groups post inter-
vention, adjusting for baseline measurements 
and covariates. For calculating mean changes of 
markers between groups, first mean changes of 
markers from baseline were calculated by [(8wk 
values-baseline values) / baseline values)] * 
100. Then, mean changes of markers between 
groups  were calculated. P<0.05 were 
considered to be statistically significant.  Health Promotion Perspectives, Vol. 3, No. 1, 2013; P: 55-63 
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Results 
 
From 65 subjects recruited, 49 subjects 
completed the trial (n= 24 in the intervention 
group; n=25 in the control group; (Fig.1). As 
shown in Table 1, initial characteristics were 
similar at baseline in both groups. 
 
 
 
Fig. 1: Trial design implemented in this study 
 
Effect of inulin supplementation on anth-
ropometric indices and dietary intakes 
As shown in Table 1, there was no sig-
nificant difference at baseline body weight and 
BMI between two groups. Two groups did 
not show significant difference in baseline di-
etary intakes, except for dietary fiber which 
was significantly higher in control group than 
in the intervention group (data not shown, 
presented in another paper
22). Post interven-
tion, body weight and BMI were significantly 
decreased in inulin group (75.45 ± 11.35 to 
72.85 ± 11.20  kg, 31.60 ± 4.09 to 30.50 ± 
4.02 kg/m2, respectively; P<0.05) while they 
remained unchanged in maltodextrin group. 
These changes were significant in inulin group 
compared to baseline (P<0.05). The results for 
dietary assessment are presented in detail in 
another paper
22. 
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Table1: Baseline characteristics of trial patients1 
 
Characteristics Control 
group (n=25) 
Intervention 
group (n=24) 
Age (yr)   48.70 ± 9.70  47.80 ± 10.10 
Weight (kg)  70.50 ±11.05  75.45 ± 11.30 
Height (cm)  153.50 ± 6.50  154.40 ± 5.80 
BMI (kg/m2)  29.90 ± 4.20  31.60 ± 4.09 
Diabetes duration (yr)  5.30 ± 4.60  7.30 ± 5.40 
Metformin 500 mg  (tablets/d)  2.70 ± 0.90  2.85 ± 1.08 
Glibenclamide 5mg (tablets/d)  1.90 ±1.20  2.35 ± 0.99 
BMI: body mass index. 1Rsults are presented as means ± standard deviation. / For all Characteristics, there were no signifi-
cant differences between Maltodextrin and Inulin groups (all Non significant, based on independent samples t tests)  
 
Briefly, there was no significant differ-
ence between groups regarding to intakes of 
energy, carbohydrate and total fat at the end 
of trial. The intake of energy and macronu-
trients remained unchanged in control group, 
while intake of energy and total fat decreased 
significantly in intervention group
22. 
 
Effects of inulin supplementation on fast-
ing blood sugar and lipid profile 
  At the beginning of trial, we did not 
observe a significant difference between inter-
vention and control groups in FBS, HbA1c and 
lipid profile (Table 2). At the end of trial, there 
was a significant decrease in FBS (8.50%), 
HbA1c (10.40%), TC (12.90%), TG (23.60 %), 
LDL-c (35.30 %), LDL-c/HDL-c ratio 
(16.25%) and TC/HDL-c ratio (25.20%) in 
the intervention group compared with the 
control group (P<0.05). Inulin supplementa-
tion caused a 19.90% increase in HDL-c, 
compared with the control group after ad-
justing for dietary intakes and baselines values 
(P<0.05). In the control group FBS, HbA1c, 
TC, TG, LDL-c, HDL-c, TC/HDL-c ratio 
and LDL-c/HDL-c ratio were not signifi-
cantly changed at the end of trail. 
 
Table 2: The effects of 8 weeks of inulin supplementation on anthropometrics indices, FBS and lipid profile dur-
ing trial1 
 
Variables Period Control
group (n=25) 
Intervention
group (n=24) 
FBS (mg/dl)  Initial  157.80 ± 10.60 161.70 ± 15.10
  End  156.10 ± 14.20 146.60 ± 19.90 a ,b
HbA1c (%)  Initial  8.20 ± 0.90 8.40 ± 0.90
  End  8.30 ± 1.09 7.70 ± 0.70 a, b
TC (mg/dl)  Initial  197.90 ± 37.80 192.50 ± 42.80
  End  203.10 ± 45.60 171.00 ± 39.70 a, b
TG (mg/dl)  Initial  213.10 ± 68.10 223.30 ± 84.20
  End  216.80 ± 59.80 169.95 ± 65.60 a ,b
LDL-c (mg/dl)  Initial  114.60 ± 35.30 110.60 ± 40.90
  End  116.30 ± 42.96 89.60 ± 41.40 a ,b
HDL-c (mg/dl)  Initial  40.60 ± 5.65 37.20 ± 6.05
  End  43.50 ± 4.20 47.40 ± 7.65 a ,b
TC / HDL-c  Initial  4.90 ± 0.90 5.30 ± 1.40
  End  4.70 ± 0.10 3.70 ±1.09 a ,b
LDL-c / HDL-c  Initial  2.80 ± 0.80 3.00 ± 1.20
  End  2.70 ± 0.95 1.95 ± 0.10 a ,b
BMI: body mass index; FBS: fasting blood sugar; TC: total cholesterol; TG: triglyceride; HDL-c: high-density lipoprotein; 
LDL-c: low-density lipoprotein. /  1Values are presented as mean ± standard deviation. a P<0.05, paired t test. b P<0.05 
analysis of covariance adjusted for dietary intakes and baseline values. 
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Discussion  
 
Beneficial effects of high fiber diets on 
prevention and management of diabetes are 
claimed
23. Therefore, we assayed the effects of 
inulin on glycemic status and lipid profile in 
type 2 diabetic patients. Our results showed 
that the inulin supplementation significantly 
decreased body weight and BMI, FBS and 
HbA1c in intervention group compared to 
control group. In addition, we observed inulin 
consumption caused a significant decrease in 
TC, TG, LDL-c, TC/HDL-c ratio and LDL-
c/HDL-c ratio in intervention compared to 
control group. The inulin supplementation 
significantly increased HDL-c compared to 
the control group.  
Pourmoradian et al. reported that royal 
jelly supplementation significantly decreased 
the mean body weight (72.45 ± 4.42 vs. 71.00 
± 6.44 kg)
24. The addition of royal jelly im-
proves the growth of L. acidophilus and B. 
bifidum. Probably, royal jelly supplementation 
may decrease weight via microfloura change
25. 
Parnell et al. reported oligofructose at a 
dose of 21 g/day for 12 weeks decreased body 
weight in healthy adults
18. We have showed 
that supplementation with inulin significantly 
decreased energy intake of the intervention 
group (1693.60 ± 250.60 to 1417.90 ± 236.70 
kcal/day,  P<0.05)
22. The mechanism(s) of 
weight reduction by inulin is not fully 
understood. Probably, some gut hormones 
such as GLP-1, PYY, and ghrelin are involved 
in weight reduction caused by inulin
18. 
Only three studies investigated the ef-
fects of fructans on glucose, insulin and lipid 
profile in type 2 DM
12-14.Yamashita et al 
showed that oligofructose (OFS) supplemen-
tation ( 8 g/day for 2 weeks) decreased fasting 
blood glucose, TC and LDL-c in type 2 DM 
patients
12. Chen et al. demonstrated that glu-
comannan, as a prebiotic, at a dose of 3.6 
g/day for 4 weeks, reduced fasting blood glu-
cose, TC and LDL-c in type 2 DM patients
26. 
Jackson et al. showed that prebiotic supple-
mentation (10 g/d inulin for 8 weeks in indi-
viduals with mild hyperlipidaemia) decreased 
fasting insulin and TG
27. Introducing of in-
ulin-enriched pasta to healthy young volun-
teers showed a significant decrease in glycemic 
status and improved lipid profile
28. Luo et al. 
and Alles et al. did not find significant changes 
with OFS supplementation (20g/d for 4 
weeks, 15g/d for 3 weeks, respectively), on 
FBS and lipid profile in type 2 DM 
patients
13,14. Additionally, the finding of 
increased HDL-c concentrations is in 
agreement with data previously obtained in 
vitro
29. In our trial, the TC: HDL-c ratio and 
LDL-c/HDL-c ratio, as atherogenic indices 
were significantly reduced in the intervention 
group compared with the control group. It is 
indicated that these ratios CVD were better 
than either serum TC or LDL-c
30.  
The difference in results obtained in 
several studies may be due to pathologic state 
and basal levels of fasting blood sugar and li-
pid profile in type 2 DM patients and type and 
dose of supplementation. 
Hypoglycemic effect of fibers can be 
explained by several mechanisms. Inulin can 
control the level of serum glucose by de-
creasing the post-meal rise of serum glucose 
and delaying entry of glucose into blood and 
retarding gastric emptying
31. Furthermore, 
modification of the gut hormones such as glu-
cagon-like peptide1 (GLP-1)
32, short- chain 
fatty acids (SCFA) which are produced from 
colonic fermentation of prebiotics
33,34 and 
reduction in the body weight and BMI
35 can 
affect glucose metabolism in the body. SCFA 
can delay gastric emptying
33. Oligofructose can 
improve glucose metabolism by rising of 
plasma insulin, β cell mass, pancreatic insulin, 
GLP-1
36 and GLP-2
37.  
Based on what is already known about the 
properties of inulin- fructans, it seems that bene-
ficial effects of inulin on lipid profile mainly me-
diated by short chain fatty acids (SCFA). Buty-
rate inhibits liver cholesterol synthesis and pro-
vides a source of energy for human colon epi-
thelial cells
38. Acetate may act as precursor for 
cholesterol synthesis, while propionate could Dehghan et al.: Effects of High Performance Inulin Supplementation … 
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inhibit hepatic cholesterol synthesis by decreas-
ing the use of acetate as a precursor of choles-
terol
39. Rossi et al. found that butyrate was the 
major fermentation product from inulin
40. Re-
duction of plasma TG may be resulted from 
decreased hepatic lipogenic capacity
41, a reduc-
tion in the hepatic lipogenic enzyme gene ex-
pression such as acetyl -COA carboxylase, malic 
enzyme, ATP citrate lyase, glucose6- phosphate, 
1-dehydrogenase and fatty acid synthase, in-
crease triacylglycerol-rich lipoprotein catabol-
ism
10,42. Glucose and insulin are main stimulator 
in the control of lipogenesis, reduction in fasting 
blood sugar and insulin levels can result in re-
duction lipogenesis
43. Moreover, prebiotics may 
contribute to cholesterol reduction by increasing 
fecal bile acid excretion
38, reducing in intestinal 
cholesterol absorption by increasing the thick-
ness of the unstirred layer in the small intestine
44, 
increase in the expression of 3-hydroxy-3-
methylglutaryl-COA reductase (HMG-COA 
reductase) and increase in the sterol regulatory 
element-binding proteins
42. 
Our trial had some limitations, including 
duration of the intervention, which seems to be 
short, lack of measurement of serum SCFA, se-
rum free fatty acids and plasma apolipoprotein.  
 
Conclusion  
 
Inulin supplementation may control le-
vels of glycemic status and improve lipid pro-
file in type 2 diabetic patients. These findings 
support the use of inulin as a safe treatment 
for managing diabetes. Our findings must be 
scrutinized in further clinical trials. 
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